News Mundipharma to market Herceptin biosimilar in key EU markets Mundipharma's third biosimilar tie-up with Celltrion
News Eisai disappointed after NICE rejects earlier use for breast... NICE says no to Halaven in second line breast cancer
News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Novartis taking aim at Pfizer with new use for breast cancer... FDA grants Breakthrough Therapy for Kisqali in premenopausal women.
News AI outperforms experts in breast cancer diagnosis Algorithms could help diagnosis of breast cancer in clinics
News Pfizer's Ibrance available across UK after thumbs up in Scot... Around 800 women have received the drug for free.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
